PSIL

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More

DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist on Hearings. The Drug Enforcement Administration is revisiting its stance on the classification of two psychedelic compounds. The agency has proposed both be listed as Schedule I substances with no recognized medical use. Benzinga Psychedelics Podcast features an expert on the ancient healing plant kanna.

Weekly Report: what happened at PSIL last week (0408-0412)?

Weekly Report: what happened at PSIL last week (0401-0405)?

Weekly Report: what happened at PSIL last week (0325-0329)?

Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence

Utah hospitals will soon provide psilocybin and MDMA therapy for mental health conditions in a pilot program. Beckley Psytech and atai announce positive initial results from a clinical trial of 5-MeO-DMT in Treatment Resistant Depression. Prosecutors in Virginia are probing whether Facebook's social media platforms are facilitating the illegal sale of drugs. Elon Musk makes the case for using psychedelics in a new episode of the Benzinga Psychedelics Podcast.

Weekly Report: what happened at PSIL last week (0318-0322)?

Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More

FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement. Psychedelics biopharma company Cybin Inc. Announced that the FDA has granted it a breakthrough therapy designation for its LSD-based treatment for anxiety disorder. The company also announced the pricing of an underwritten offering of $175 million in shares.

Weekly Report: what happened at PSIL last week (0311-0315)?